Bausch Health Companies Investor Conference Presentation Deck
Accelerating Strategic Alternatives to Drive Shareholder Value ¹
We expect to launch the Solta Medical IPO in
Dec. 2021/Jan. 2022 timeframe, subject to market
conditions and regulatory, stock exchange and other
approvals
SOLTAMEDICAL'
BAUSCH + LOMB
$1.1B
of debt repaid in 3Q21;
$500M using cash on hand and cash
generated from operations and $600M in
connection with the Amoun divestiture
BAUSCH- Health
We expect to launch the Bausch + Lomb IPO-30 days after
the Solta Medical IPO, subject to market conditions and
regulatory, stock exchange and other approvals
Spinoff to occur following the expiry of customary lock-ups and
achievement of our target net leverage ratios4
Significant De-Leveraging Progress Made
$1.6B
YTD debt repayment as of 9/30/21²
6.4x
total company net leverage,
as of 9/30/21
(pro forma for Amoun divestiture)³
This presentation does not constitute an offer to sell or the solicitation of an offer to buy any securities.
1. Subject to forward looking statements.
2. Subsequent to 9/30/21, the Company drew down a net amount of $365M on the revolving credit facility.
3. Trailing Twelve Months Adj. EBITDA (Non-GAAP) adjusted to exclude the contribution of -$70M from the divested Amoun business over that period. See Slide 2 and Appendix for further non-GAAP information.
4. Subject to receipt of applicable shareholder and other necessary approvals and the achievement of our target net leverage ratios (Bausch+Lomb <2.5x and Bausch Pharma -6.5x-6.7x at the time of the spinoff).View entire presentation